Health Care

4476 posts

Radiopharm Theranostics doses first patient in prostate cancer clinical study

Radiopharm Theranostics has dosed the first patient in its phase one clinical trial of a potential…

Nexsen accelerates global rollout for StrepSure

Nexen’s StrepSure diagnostic platform has received initial backing from the US Food and Drug Administration (FDA).

Radiopharma player Cyclopharm secures multi-site agreement in the States

Cyclopharm has signed a further multi-site agreement with leading US academic health system operator Northwestern Memorial…
Hong Kong coastline drone shot

Paradigm Biopharma activates Hong Kong trial site for Phase III osteo trial for iPPS

Paradigm Biopharmaceuticals (ASX:PAR) has kicked off the screening process for participants with osteoarthritis ahead of the company’s Hong Kong-based
Doctor at SNT

Existing myleofibrosis drugs can make the condition worse. Syntara Ltd could be about to change that 

In the face of a new war crisis weighing heavily on both equities and economics alike, value hunters (both long- and short-term minded
3D model of a brain concept

Some 80% of people who develop Parkinson’s present with this sleep disorder first. Syntara’s treating it

Syntara has today added ~$2 million to its coffers – $1.7M to be exact – after…
Nasal spray

Two days after Tetratherix moves to GLP-1 nasal drugs, HSBC analysts say thematic overhyped

After announcing it'd be moving into the GLP-1 weight loss drugs space, Tetratherix has dropped as…

Oneview Healthcare to raise $21M to back AI developments

Oneview Healthcare is raising $21 million to support its pipeline of AI backed developments and new…
Nasal spray user

Tetratherix, which focuses on post-surgery skin healing, eyes new product: Nasal Ozempic

Tetratherix is pivoting into one interesting class of biotech product well outside its existing focus on…

BlinkLab forms partnership with US autism foundation

BlinkLab’s collaboration the SHANK2 foundation will provide it with access to genetically confirmed patient populations.